This website will close on 30 April 2024. After this date, your content will not be accessible. Please contact info@healthinnovationnwc.nhs.uk for more information.

Under evaluation with potential for adoption
Share innovation

Deontics Innovative Clinical Decision Support (CDSS)

By Andy Bogue, Deontics Added 9th May, 2019 Updated 3rd Sep, 2019

Deontics is an Artificial Intelligence (AI) company with world-leading clinical pathway/workflow and clinical decision support technologies following 25 years development with multiple organisations. Our solution encodes conventional knowledge including guidelines, quality measures and clinical trial inclusion/exclusion criteria into a standard digital format for enterprise wide sharing. Integration with individual patient data and patient preferences provides the best quality care options for patients and the quickest most cost effective treatment for institutions. Improved compliance with clinically proven guidelines ensures better patient outcomes whilst reducing operational costs through clinical efficiency improvements. 

About

Deontics is an Artificial Intelligence (AI) company with world-leading clinical pathway/workflow and clinical decision support technologies following 25 years academic development with Carnegie Mellon University, the Medical Research Council, Cancer Research UK, Oxford University and University College London.

Our solution enables conventional knowledge including guidelines, quality measures and clinical trial inclusion/exclusion criteria to be encoded into a standard digital format for enterprise wide sharing and integration with individual patient data and patient preferences, to provide best quality care options for patients and the quickest most cost effective treatment for institutions. Improved compliance with clinically proven guidelines ensures better patient outcomes whilst reducing operational costs through efficiency, reduced admissions, reduced length of stay and reduced chance of readmission through effective post discharge support. Reduced risk to patients means reduced medical legal costs, and improved efficiency reduces potential imposed fines. Quick wins at low cost. 

A patient facing tool is also available, providing patients with valuable advice based on guidelines and their own preferences leading to more meaningful consultations. Use of such tools has already demonstrated potential savings of £77M in unnecessary treatments, 60% increase in trial enrolment and a considerable reduction in medical errors, resulting in reduced medical legal costs.

Related Innovations